Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Receivables (2016 - 2025)

Historic Receivables for Evogene (EVGN) over the last 15 years, with Q3 2025 value amounting to $2.0 million.

  • Evogene's Receivables fell 4954.43% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 4954.43%. This contributed to the annual value of $3.2 million for FY2024, which is 525.53% down from last year.
  • Latest data reveals that Evogene reported Receivables of $2.0 million as of Q3 2025, which was down 4954.43% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Evogene's Receivables ranged from a high of $4.1 million in Q2 2024 and a low of $1.6 million during Q2 2023
  • Its 5-year average for Receivables is $2.7 million, with a median of $2.8 million in 2021.
  • As far as peak fluctuations go, Evogene's Receivables surged by 15497.81% in 2024, and later plummeted by 5604.13% in 2025.
  • Over the past 5 years, Evogene's Receivables (Quarter) stood at $2.9 million in 2021, then tumbled by 37.59% to $1.8 million in 2022, then surged by 81.97% to $3.3 million in 2023, then fell by 5.26% to $3.2 million in 2024, then crashed by 36.83% to $2.0 million in 2025.
  • Its Receivables was $2.0 million in Q3 2025, compared to $1.8 million in Q2 2025 and $3.3 million in Q1 2025.